AU2002352797A1 - Methods for identifying and validating potential drug targets - Google Patents

Methods for identifying and validating potential drug targets Download PDF

Info

Publication number
AU2002352797A1
AU2002352797A1 AU2002352797A AU2002352797A AU2002352797A1 AU 2002352797 A1 AU2002352797 A1 AU 2002352797A1 AU 2002352797 A AU2002352797 A AU 2002352797A AU 2002352797 A AU2002352797 A AU 2002352797A AU 2002352797 A1 AU2002352797 A1 AU 2002352797A1
Authority
AU
Australia
Prior art keywords
protein
disease
expression
nucleic acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002352797A
Other languages
English (en)
Inventor
Iris Alroy
Danny Ben-Avraham
Tsvika Greener
Avishai Levy
Yuval Reiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Inc
Original Assignee
Proteologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Inc filed Critical Proteologics Inc
Publication of AU2002352797A1 publication Critical patent/AU2002352797A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/9015Ligases (6)
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
AU2002352797A 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets Abandoned AU2002352797A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33170101P 2001-11-19 2001-11-19
US60/331,701 2001-11-19
PCT/US2002/037146 WO2003043580A2 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets

Publications (1)

Publication Number Publication Date
AU2002352797A1 true AU2002352797A1 (en) 2003-06-10

Family

ID=23295003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002352797A Abandoned AU2002352797A1 (en) 2001-11-19 2002-11-19 Methods for identifying and validating potential drug targets

Country Status (7)

Country Link
US (1) US20030194725A1 (https=)
EP (1) EP1456647A4 (https=)
JP (1) JP2005525790A (https=)
AU (1) AU2002352797A1 (https=)
CA (1) CA2468107A1 (https=)
IL (1) IL162062A0 (https=)
WO (1) WO2003043580A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049607A1 (en) * 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
CN1926551B (zh) * 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
EP2044247A4 (en) * 2006-07-11 2010-07-21 Avalon Pharmaceuticals CHEMIO-SELECTIVE IDENTIFICATION OF THERAPEUTIC PRODUCTS
WO2018168777A1 (ja) * 2017-03-13 2018-09-20 学校法人関西学院 嚢胞性線維症予防又は治療剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5723750A (en) * 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US6001619A (en) * 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6278039B1 (en) * 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
CA2308582A1 (en) * 1997-11-06 1999-05-20 Fred Hutchinson Cancer Research Center Method for identifying drug targets
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000008181A2 (en) * 1998-08-07 2000-02-17 Onyx Pharmaceuticals, Inc. Chp polypeptide, a ligand of pak65
AU767507B2 (en) * 1998-08-28 2003-11-13 New York University Novel ubiquitin ligases as therapeutic targets
AU6158799A (en) * 1998-10-13 2000-05-01 Onyx Pharmaceuticals, Inc. Novel cell signaling polypeptides and nucleic acids
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
CA2362520A1 (en) * 1999-02-26 2000-08-31 Joan W. Conaway Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
EP1988165A1 (en) * 1999-03-31 2008-11-05 The University of North Carolina at Chapel Hill Isolated DNA encoding cullin regulator ROC1, isolated proteins encoded by the same, and methods utilizing the same
AU6611900A (en) * 1999-07-30 2001-03-13 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
PT1309726E (pt) * 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6610489B2 (en) * 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
EP1442062A4 (en) * 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA

Also Published As

Publication number Publication date
WO2003043580A3 (en) 2004-04-15
JP2005525790A (ja) 2005-09-02
EP1456647A4 (en) 2006-10-18
WO2003043580A2 (en) 2003-05-30
IL162062A0 (en) 2005-11-20
US20030194725A1 (en) 2003-10-16
CA2468107A1 (en) 2003-05-30
EP1456647A2 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
US7193069B2 (en) Full-length cDNA
Kubo et al. Cys2/His2 zinc-finger protein family of petunia: evolution and general mechanism of target-sequence recognition
US6943241B2 (en) Full-length cDNA
Eystathioy et al. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles
Pic et al. The forkhead protein Fkh2 is a component of the yeast cell cycle transcription factor SFF
US7122373B1 (en) Human genes and gene expression products V
EP1440981A2 (en) Full-length human cdna
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
Hasegawa et al. Distinct roles for Khd1p in the localization and expression of bud-localized mRNAs in yeast
Phillips et al. Identification and characterization of SNX15, a novel sorting nexin involved in protein trafficking
EP1308459A2 (en) Full-length cDNA sequences
EP1293569A2 (en) Full-length cDNAs
US20070020637A1 (en) Full-length cDNA
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
CA2459219A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
Sudarshan et al. Recurrent chromosomal translocations in sarcomas create a megacomplex that mislocalizes NuA4/TIP60 to Polycomb target loci
Karakostis et al. p53 mRNA and p53 protein structures have evolved independently to interact with MDM2
US20070048740A1 (en) Full-length cDNA
EP1447413A2 (en) Full-length human cDNA
EP1509539A2 (en) Novel compositions and methods for cancer
EP1469769A2 (en) Novel compositions and methods for cancer
Grisendi et al. Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor
AU2002352797A1 (en) Methods for identifying and validating potential drug targets
Jabbour et al. Sequence, gene structure, and expression pattern of CTNNBL1, a minor-class intron-containing gene—evidence for a role in apoptosis
Li et al. Transcriptional activation through interaction of MBF2 with TFIIA

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted